Delivery and performance of surfactant replacement therapies to treat pulmonary disorders

References

• 1  Zasadzinski JA, Stenger PC, Shieh I, Dhar P. Overcoming rapid inactivation of lung surfactant: analogies between competitive adsorption and colloid stability. Biochim. Biophys. Acta1798(4),801–828 (2010).
  Medline CASGoogle Scholar
• 2  Notter RH. Introduction to surface tension and surfactants. Lung surfactants: basic science and clinical applications, volume 149. Lenfant C (Ed.). Marcel Dekker, NY, USA, 7–39 (2000).
  Google Scholar
• 3  Zasadzinski J, Ding J, Warriner H, Bringezu F, Waring AJ. The physics and physiology of lung surfactants. Curr. Opin. Colloid Interface Sci.6(5),506–513 (2001).
  CASGoogle Scholar
• 4  Gower WA, Nogee LM. Surfactant dysfunction. Paediatr. Respir. Rev.12(4),223–229 (2011).
  MedlineGoogle Scholar
• 5  Kaviratna A, Banerjee R, Singh Rao S, Shah A. Pulmonary surfactant nanostructures and their implications. Dyn. Biochem. Process. Biotechnol. Mol. Biol.3,21–32 (2009).
  Google Scholar
• 6  Nkadi PO, Merritt TA, Pillers D-AM. An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease. Mol. Genet. Metab.97(2),95–101 (2009).
  Medline CASGoogle Scholar
• 7  Hallman M, Glumoff V, Ramet M. Surfactant in respiratory distress syndrome and lung injury. Comp. Biochem. Physiol. A Mol. Integr. Physiol.129(1),287–294 (2001).
  Medline CASGoogle Scholar
• 8  Blanco O, Pérez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient pulmonary surfactant. Eur. J. Pharmacol.568(1),1–15 (2007).
  Medline CASGoogle Scholar
• 9  Saxena S. Lung surfactant. Resonance10(8),91–96 (2005).
  Google Scholar
• 10  Frerking I, Günther A, Seeger W, Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med.27(11),1699–1717 (2001).
  Medline CASGoogle Scholar
• 11  Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Engl. J. Med.344(8),573–579 (2001).
  Medline CASGoogle Scholar
• 12  Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N. Engl. J. Med.350(13),1296–1303 (2004).
  Medline CASGoogle Scholar
• 13  Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. Pediatr. Dev. Pathol.12(4),253–274 (2009).
  Medline CASGoogle Scholar
• 14  Nogee LM. Genetic mechanisms of surfactant deficiency. Neonatology85(4),314–318 (2004).
  Google Scholar
• 15  Willson DF, Notter RH. The future of exogenous surfactant therapy. Respir. Care56(9),1369–1388 (2011).
  MedlineGoogle Scholar
• 16  Zuo YY, Veldhuizen RA, Neumann AW, Petersen NO, Possmayer F. Current perspectives in pulmonary surfactant – inhibition, enhancement and evaluation. Biochim. Biophys. Acta1778(10),1947–1977 (2008).
  Medline CASGoogle Scholar
• 17  Gunasekara L, Schoel WM, Schürch S, Amrein MW. A comparative study of mechanisms of surfactant inhibition. Biochim. Biophys. Acta1778(2),433–444 (2008).
  Medline CASGoogle Scholar
• 18  Kaviratna A, Banerjee R. The effect of acids on dipalmitoyl phosphatidylcholine (DPPC) monolayers and liposomes. Colloids Surf. A Physicochem. Eng. Asp.345(1),155–162, (2009)
  CASGoogle Scholar
• 19  Gunasekara L, Schürch S, Schoel WM et al. Pulmonary surfactant function is abolished by an elevated proportion of cholesterol. Biochim. Biophys. Acta1737(1),27–35 (2005).
  Medline CASGoogle Scholar
• 20  Pallem V, Kaviratna A, Chimote G, Banerjee R. Effect of meconium on surface properties of surfactant monolayers and liposomes. Colloids Surf. A Physicochem. Eng. Asp.370(1),6–14 (2010).
  CASGoogle Scholar
• 21  Lopez-Rodriguez E, Echaide M, Cruz A, Taeusch HW, Perez-Gil J. Meconium impairs pulmonary surfactant by a combined action of cholesterol and bile acids. Biophys. J.100(3),646–655 (2011).
  Medline CASGoogle Scholar
• 22  Mazela J, Merritt TA, Gadzinowski J, Sinha S. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases. Acta Paediatr.95(9),1036–1048 (2006).
  MedlineGoogle Scholar
• 23  Robertson B, Halliday HL. Principles of surfactant replacement. Biochim. Biophys. Acta1408(2),346–361 (1998).
  Medline CASGoogle Scholar
• 24  Stevens TP, Sinkin RA. Surfactant replacement therapy. Chest131(5),1577–1582 (2007).
  MedlineGoogle Scholar
• 25  Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics121(2),419–432 (2008).
  MedlineGoogle Scholar
• 26  Poulain F, Clements J. Pulmonary surfactant therapy. West. J. Med.162(1),43 (1995).
  Medline CASGoogle Scholar
• 27  Schneider HA, Hallman M, Benirschke K, Gluck L. Human surfactant: a therapeutic trial in premature rabbits. J. Pediatr.100(4),619–622 (1982).
  Medline CASGoogle Scholar
• 28  King RJ, Ruch J, Gikas EG, Platzker A, Creasy RK. Appearance of paoproteins of pulmonary surfactant in human amniotic fluid. J. Appl. Physiol.39(5),735–741 (1975).
  Medline CASGoogle Scholar
• 29  Hallman M, Merritt TA, Schneider H et al. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics71(4),473–482 (1983).
  Medline CASGoogle Scholar
• 30  Hallman M, Merritt TA, Jarvenpaa A-L et al. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J. Pediatr.106(6),963–969 (1985).
  Medline CASGoogle Scholar
• 31  Merritt TA, Hallman M, Bloom BT et al. Prophylactic treatment of very premature infants with human surfactant. N. Engl. J. Med.315(13),785 (1986).
  Medline CASGoogle Scholar
• 32  Merritt TA, Hallman M, Berry C et al. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J. Pediatr.118(4),581–594 (1991).
  Medline CASGoogle Scholar
• 33  Lang MJ, Hall RT, Reddy NS, Kurth CG, Merritt TA. A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. J. Pediatr.116(2),295–300 (1990).
  Medline CASGoogle Scholar
• 34  Vaucher YE, Merritt TA, Hallman M, Jarvenpaa A-L, Telsey AM, Jones BL. Neurodevelopmental and respiratory outcome in early childhood after human surfactant treatment. Arch. Pediatr. Adolesc. Med.142(9),927 (1988).
  CASGoogle Scholar
• 35  Speer CP, Gefeller O, Groneck P et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch. Dis. Child. Fetal Neonatal Ed.72(1),F8–F13 (1995).
  Medline CASGoogle Scholar
• 36  Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur. J. Pediatr.162(7–8),476–480 (2003).
  Medline CASGoogle Scholar
• 37  Griese M, Dietrich P, Reinhardt D. Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. Am. J. Respir. Crit. Care Med.152(3),1050–1054 (1995).
  Medline CASGoogle Scholar
• 38  Bloom BT, Kattwinkel J, Hall RT et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics100(1),31–38 (1997).
  Medline CASGoogle Scholar
• 39  Dhar P, Eck E, Israelachvili JN et al. Lipid–protein interactions alter line tensions and domain size distributions in lung surfactant monolayers. Biophys. J.102(1),56–65 (2012).
  Medline CASGoogle Scholar
• 40  Alarie Y, Robillard E. Modifications of pressure-volume curves in rat lungs after inhalation of surface active extracts and agents. Physiologist6,128 (1963).
  Google Scholar
• 41  Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Microaerosol administration of synthetic β-γ-dipalmitoyl-L-α-lecithin in the respiratory distress syndrome: a preliminary report. CMAJ90(2),55 (1964).
  Medline CASGoogle Scholar
• 42  Ivey H, Roth S, Kattwinkel J, Blizzard R. Nebulization of sonicated phospholipids (PL) for treatment of respiratory distress syndrome (RDS) of infancy. Pediatr. Res.11(4),573–573 (1977).
  Google Scholar
• 43  Fujiwara T, Chida S, Watabe Y, Maeta H, Morita T, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet315(8159),55–59 (1980).
  Google Scholar
• 44  Morley C, Miller N, Bangham A, Davis J. Dry artificial lung surfactant and its effect on very premature babies. Lancet317(8211),64–68 (1981).
  Google Scholar
• 45  Long W, Thompson T, Sundell H, Schumacher R, Volberg F, Guthrie R. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. J. Pediatr.118(4),595–605 (1991).
  Medline CASGoogle Scholar
• 46  Sáenz A, Álvarez L, Santos M et al. Beneficial effects of synthetic KL₄ surfactant in experimental lung transplantation. Eur. Respir. J.37(4),925–932 (2011).
  Medline CASGoogle Scholar
• 47  Wiswell TE, Smith RM, Katz LB et al. Bronchopulmonary segmental lavage with Surfaxin (KL₄-surfactant) for acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med.160(4),1188–1195 (1999).
  Medline CASGoogle Scholar
• 48  Waring A, Walther F, Gordon L et al. The role of charged amphipathic helices in the structure and function of surfactant protein B. J. Peptide Res.66(6),364–374 (2005).
  Medline CASGoogle Scholar
• 49  Sarker M, Waring AJ, Walther FJ, Keough KM, Booth V. Structure of Mini-B, a functional fragment of surfactant protein B, in detergent micelles. Biochemistry46(39),11047–11056 (2007).
  Medline CASGoogle Scholar
• 50  Walther FJ, Waring AJ, Hernandez-Juviel JM et al. Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs. PLoS ONE5(1),e8672 (2010).
  MedlineGoogle Scholar
• 51  Spragg RG, Lewis JF, Walmrath H-D et al. Effect of recombinant surfactant protein C–based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med.351(9),884–892 (2004).
  Medline CASGoogle Scholar
• 52  Spragg RG, Lewis JF, Wurst W et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am. J. Respir. Crit. Care Med.167(11),1562–1566 (2003).
  MedlineGoogle Scholar
• 53  Johansson J, Some M, Linderholm B-M, Almlén A, Curstedt T, Robertson B. A synthetic surfactant based on a poly-Leu SP-C analog and phospholipids: effects on tidal volumes and lung gas volumes in ventilated immature newborn rabbits. J. Appl. Physiol.95(5),2055–2063 (2003).
  Medline CASGoogle Scholar
• 54  Walther FJ, David-Cu R, Leung C et al. A synthetic segment of surfactant protein A: structure, in vitro surface activity, and in vivo efficacy. Pediatr. Res.39(6),938–946 (1996).
  Medline CASGoogle Scholar
• 55  Clark H, Reid K. The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema. Arch. Dis. Child88(11),981–984 (2003).
  Medline CASGoogle Scholar
• 56  Lu KW, Pérez-Gil J, Echaide M, Taeusch HW. Pulmonary surfactant proteins and polymer combinations reduce surfactant inhibition by serum. Biochim. Biophys. Acta1808(10),2366–2373 (2011).
  Medline CASGoogle Scholar
• 57  Lu KW, Taeusch HW. Combined effects of polymers and KL₄ peptide on surface activity of pulmonary surfactant lipids. Biochim. Biophys. Acta1798(6),1129–1134 (2010).
  Medline CASGoogle Scholar
• 58  Hudak ML, Martin DJ, Egan EA et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics100(1),39–50 (1997).
  Medline CASGoogle Scholar
• 59  Halliday H. Overview of clinical trials comparing natural and synthetic surfactants. Neonatology67(Suppl. 1),32–47 (2009).
  Google Scholar
• 60  Bernhard W, Mottaghian J, Gebert A, Rau GA, Von Der Hardt H, Poets CF. Commercial versus native surfactants surface activity, molecular components, and the effect of calcium. Am. J. Respir. Crit. Care Med.162(4),1524–1533 (2000).
  Medline CASGoogle Scholar
• 61  Sato A, Ikegami M. SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung. PLoS ONE7(7),e39392 (2012).
  Medline CASGoogle Scholar
• 62  Seehase M, Collins JJ, Kuypers E et al. New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs. PLoS ONE7(10),e47631 (2012).
  Medline CASGoogle Scholar
• 63  Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B. Resistance of different surfactant preparations to inactivation by meconium. Pediatr. Res.50(1),44–49 (2001).
  Medline CASGoogle Scholar
• 64  Moya F, Sinha S, Gadzinowski J et al. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics119(6),e1361–e1370 (2007).
  MedlineGoogle Scholar
• 65  Wright J, Benson B, Williams M, Georke J, Clements J. Protein composition of rabbit alveolar surfactant subfractions. Biochim. Biophys. Acta791(3),320–332 (1984).
  Medline CASGoogle Scholar
• 66  Magoon MW, Wright JR, Baritussio A et al. Subfractionation of lung surfactant implications for metabolism and surface activity. Biochim. Biophys. Acta750(1),18–31 (1983).
  Medline CASGoogle Scholar
• 67  Gross NJ, Narine K. Surfactant subtypes in mice: characterization and quantitation. J. Appl. Physiol.66(1),342–349 (1989).
  Medline CASGoogle Scholar
• 68  Manalo E, Merritt T, Amirkhanian J, Kheiter A. Characterization of surfactant subtypes of beractant and a synthetic peptide containing surfactant KL₄ following surface area cycling and addition of fibrinogen. Lung175(4),225–233 (1997).
  Medline CASGoogle Scholar
• 69  Halliday H. Surfactants: past, present and future. J. Perinatol.28,S47–S56 (2008).
  Medline CASGoogle Scholar
• 70  Phibbs RH, Tooley WH, Ballard RA et al. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics88(1),1–9 (1991).
  Medline CASGoogle Scholar
• 71  Halpern D, Fujioka H, Takayama S, Grotberg JB. Liquid and surfactant delivery into pulmonary airways. Respir. Physiol. Neurobiol.163(1),222–231 (2008).
  Medline CASGoogle Scholar
• 72  Cassidy K, Bull J, Glucksberg M et al. A rat lung model of instilled liquid transport in the pulmonary airways. J. Appl. Physiol.90(5),1955–1967 (2001).
  Medline CASGoogle Scholar
• 73  Valls-I-Soler A, Fernández-Ruanova B, López-Heredia y Goya J, Etxebarría LR, Rodriguez-Soriano J, Carretero V. A randomized comparison of surfactant dosing via a dual-lumen endotracheal tube in respiratory distress syndrome. Pediatrics101(4),e4 (1998).
  Medline CASGoogle Scholar
• 74  Schermuly R, Schmehl T, Günther A, Grimminger F, Seeger W, Walmrath D. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury impact on gas exchange. Am. J. Respir. Crit. Care Med.156(2),445–453 (1997).
  Medline CASGoogle Scholar
• 75  Shah S. Exogenous surfactant: intubated present, nebulized future? World J. Pediatr.7(1),11–15 (2011).
  MedlineGoogle Scholar
• 76  Gupta S, Donn SM. Novel approaches to surfactant administration. Crit. Care Res. Pract.2012,278483 (2012).
  MedlineGoogle Scholar
• 77  Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M. Implementation of surfactant treatment during continuous positive airway pressure. J. Perinatol.27(7),422–427 (2007).
  Medline CASGoogle Scholar
• 78  Dani C, Corsini I, Poggi C. Risk factors for intubation-surfactant-extubation (INSURE) failure and multiple INSURE strategy in preterm infants. Early Hum. Dev.88,S3 (2012).
  MedlineGoogle Scholar
• 79  Kribs A, Pillekamp F, Hünseler C, Vierzig A, Roth B. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age ≤27 weeks). Pediatr. Anesth.17(4),364–369 (2007).
  MedlineGoogle Scholar
• 80  Kribs A. Early administration of surfactant in spontaneous breathing with nCPAP through a thin endotracheal catheter – an option in the treatment of RDS in ELBW infants. J. Perinatol.29(3),256–256 (2009).
  Medline CASGoogle Scholar
• 81  Kribs A, Härtel C, Kattner E et al. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin. Padiatr.222(1),13–17 (2010).
  MedlineGoogle Scholar
• 82  Kribs A, Vierzig A, Hünseler C et al. Early surfactant in spontaneously breathing with nCPAP in ELBW infants – a single centre four year experience. Acta Paediatr.97(3),293–298 (2008).
  MedlineGoogle Scholar
• 83  Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch. Dis. Child. Fetal Neonatal Ed.96(4),F243–F248 (2011).
  MedlineGoogle Scholar
• 84  Kattwinkel J, Robinson M, Bloom BT, Delmore P, Ferguson JE. Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J. Perinatol.24(6),360–365 (2004).
  Medline CASGoogle Scholar
• 85  Trevisanuto D, Grazzina N, Ferrarese P, Micaglio M, Verghese C, Zanardo V. Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Neonatology87(4),217–220 (2005).
  CASGoogle Scholar
• 86  Barbosa RF, Marcatto JDO, Silva ACS, Silva YP. ProSealTM laryngeal mask airway for surfactant administration in the treatment of respiratory distress syndrome in a premature infant. Revista Brasileira de Terapia Intensiva24(2),207–210 (2012).
  MedlineGoogle Scholar
• 87  Roberts KD, Lampland AL, Meyers PA, Worwa CT, Plumm BJ, Mammel MC. Laryngeal mask airway for surfactant administration in a newborn animal model. Pediatr. Res.68,414–418 (2010).
  Medline CASGoogle Scholar
• 88  Trevisanuto D, Micaglio M, Ferrarese P, Zanardo V. The laryngeal mask airway: potential applications in neonates. Arch. Dis. Child. Fetal Neonatal Ed.89(6),F485–F489 (2004).
  Medline CASGoogle Scholar
• 89  Gupta S. Laryngeal mask airway for babies: uncharted waters. Resuscitation82,1373–1374 (2011).
  MedlineGoogle Scholar
• 90  Petrikovsky B, Lysikiewicz A, Markin L, Slomko Z. In utero surfactant administration to preterm human fetuses using endoscopy. Fetal Diagn. Ther.10(2),127–130 (2009).
  Google Scholar
• 91  Mazela J, Polin RA. Aerosol delivery to ventilated newborn infants: historical challenges and new directions. Eur. J. Pediatr.170(4),433–444 (2011).
  MedlineGoogle Scholar
• 92  Lewis JF, Ikegami M, Jobe A, Tabor B. Aerosolized surfactant treatment of preterm lambs. J. Appl. Physiol.70(2),869–876 (1991).
  Medline CASGoogle Scholar
• 93  Lewis JF, Tabor B, Ikegami M, Jobe A, Joseph M, Absolom D. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. J. Appl. Physiol.74(3),1256–1264 (1993).
  Medline CASGoogle Scholar
• 94  Schermuly RT, Günther A, Weissmann N et al. Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury. Am. J. Respir. Crit. Care Med.161(1),152–159 (2000).
  Medline CASGoogle Scholar
• 95  Corcoran TE, Thomas KM, Garoff S, Tilton RD, Przybycien TM, Pilewski JM. Imaging the postdeposition dispersion of an inhaled surfactant aerosol. J. Aerosol Med. Pulm. Drug Deliv.25(5),290–296 (2012).
  Medline CASGoogle Scholar
• 96  Dhand R. Basic techniques for aerosol delivery during mechanical ventilation. Respir. Care49(6),611–622 (2004).
  MedlineGoogle Scholar
• 97  Jorch G, Hartl H, Roth B et al. To the editor: surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr. Pulmonol.24(3),222–224 (1997).
  Medline CASGoogle Scholar
• 98  Finer N. To intubate or not – that is the question: continuous positive airway pressure versus surfactant and extremely low birthweight infants. Arch. Dis. Child. Fetal Neonatal Ed.91(6),F392–F394 (2006).
  Medline CASGoogle Scholar
• 99  Berggren E, Liljedahl M, Winbladh B et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr.89(4),460–464 (2000).
  Medline CASGoogle Scholar
• 100  Ellyett K, Broadbent R, Fawcett E, Campbell A. Surfactant aerosol treatment of respiratory distress syndrome in the spontaneously breathing premature rabbit. Pediatr. Res.39(6),953–957 (1996).
  Medline CASGoogle Scholar
• 101  Sun Y, Yang R, Zhong J et al. Aerosolised surfactant generated by a novel noninvasive apparatus reduced acute lung injury in rats. Crit. Care13(2),R31 (2009).
  MedlineGoogle Scholar
• 102  Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R. An open label, pilot study of Aerosurf^® combined with nCPAP to prevent RDS in preterm neonates. J. Aerosol Med. Pulm. Drug Deliv.23(5),303–309 (2010).
  Medline CASGoogle Scholar
• 103  Arzhavitina A, Steckel H. Surface active drugs significantly alter the drug output rate from medical nebulizers. Int. J. Pharm.384(1),128–136 (2010).
  Medline CASGoogle Scholar
• 104  Lewis J, Ikegami M, Higuchi R, Jobe A, Absolom D. Nebulized vs. instilled exogenous surfactant in an adult lung injury model. J. Appl. Physiol.71(4),1270–1276 (1991).
  Medline CASGoogle Scholar
• 105  Lewis JF, Mccaig L. Aerosolized versus instilled exogenous surfactant in a nonuniform pattern of lung injury. Am. J. Respir. Crit. Care Med.148(5),1187–1193 (1993).
  CASGoogle Scholar
• 106  Rey-Santano C, Mielgo VE, Andres L, Ruiz-Del-Yerro E, Valls-I-Soler A, Murgia X. Acute and sustained effects of aerosolized vs. bolus surfactant therapy in premature lambs with respiratory distress syndrome. Pediatr. Res.73(5),639–646 (2013).
  Medline CASGoogle Scholar
• 107  Vervaet C, Byron PR. Drug–surfactant–propellant interactions in HFA-formulations. Int. J. Pharm.186(1),13–30 (1999).
  Medline CASGoogle Scholar
• 108  Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically ventilated patients. Clin. Chest Med.29(2),277–296 (2008).
  MedlineGoogle Scholar
• 109  Ruppert C, Kuchenbuch T, Boensch M et al. Dry powder aerosolization of a recombinant surfactant protein-C-based surfactant for inhalative treatment of the acutely inflamed lung. Crit. Care Med.38(7),1584–1591 (2010).
  Medline CASGoogle Scholar
• 110  Pohlmann G, Iwatschenko P, Koch W et al. A novel continuous powder aerosolizer (CPA) for inhalative administration of highly concentrated recombinant surfactant protein-C (rSP-C) surfactant to preterm neonates. J. Aerosol Med. Pulm. Drug Deliv. doi:10.1089/jamp.2012.0996 (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 111  Nimmo AJ, Carstairs JR, Patole SK, Whitehall J, Davidson K, Vink R. Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin. Exp. Pharmacol. Physiol.29(8),661–665 (2002).
  Medline CASGoogle Scholar
• 112  Hughes WT, Sillos EM, Lafon S et al. Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. J. Infect. Dis.177(4),1046–1056 (1998).
  Medline CASGoogle Scholar
• 113  Veen AVT, Mouton JW, Gommers D, Lachmann B. Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br. J. Pharmacol.119(6),1145–1148 (1996).
  MedlineGoogle Scholar
• 114  Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am. J. Obstet. Gynecol.168(2),508 (1993).
  Medline CASGoogle Scholar
• 115  Kari MA, Eronen M, Virtanen M et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics93(5),730–736 (1994).
  Medline CASGoogle Scholar
• 116  Silver RK, Vyskocil C, Solomon SL, Ragin A, Neerhof MG, Farrell EE. Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered before 30 weeks’ gestation. Obstet. Gynecol.87(5, Part 1),683–691 (1996).
  Medline CASGoogle Scholar
• 117  Costa S, Zecca E, De Luca D, De Carolis MP, Romagnoli C. Efficacy of a single dose of antenatal corticosteroids on morbidity and mortality of preterm infants. Eur. J. Obstet. Gynecol. Reprod. Biol.131(2),154–157 (2007).
  Medline CASGoogle Scholar
• 118  Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP, Milligan J. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics76(2),145–153 (1985).
  Medline CASGoogle Scholar
• 119  Shapiro DL, Notter RH, Morin FC 3rd et al. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics76(4),593–599 (1985).
  Medline CASGoogle Scholar
• 120  Kwong MS, Egan EA, Notter RH, Shapiro DL. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics76(4),585–592 (1985).
  Medline CASGoogle Scholar
• 121  Dunn MS, Shennan AT, Zayack D, Possmayer F. Bovine surfactant replacement therapy in neonates of less than 30 weeks’ gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics87(3),377–386 (1991).
  Medline CASGoogle Scholar
• 122  Kendig JW, Notter RH, Cox C et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks’ gestation. N. Engl. J. Med.324(13),865–871 (1991).
  Medline CASGoogle Scholar
• 123  Kattwinkel J, Bloom BT, Delmore P et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks’ gestation. Pediatrics92(1),90–98 (1993).
  Medline CASGoogle Scholar
• 124  Kääpä P, Seppänen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J. Pediatr.123(1),115–119 (1993).
  Medline CASGoogle Scholar
• 125  Abbasi S, Bhutani VK, Gerdes JS. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. J. Pediatr.122(3),446–452 (1993).
  Medline CASGoogle Scholar
• 126  Kraybill EN, Bose CL, Corbet AJ et al. Double-blind evaluation of developmental and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo. J. Pediatr.126(5),S33–S42 (1995).
  Medline CASGoogle Scholar
• 127  Corbet A, Long W, Schumacher R, Gerdes J, Cotton R. Double-blind developmental evaluation at 1-year corrected age of 597 premature infants with birth weights from 500 to 1350 grams enrolled in three placebo-controlled trials of prophylactic synthetic surfactant. J. Pediatr.126(5),S5–S12 (1995).
  Medline CASGoogle Scholar
• 128  Halliday H, Tarnow-Mordi W, Corcoran J, Patterson C. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch. Dis. Child69(3),276–280 (1993).
  Medline CASGoogle Scholar
• 129  Verder H, Robertson B, Greisen G et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N. Engl. J. Med.331(16),1051–1055 (1994).
  Medline CASGoogle Scholar
• 130  Verder H, Albertsen P, Ebbesen F et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation. Pediatrics103(2),e24–e24 (1999).
  Medline CASGoogle Scholar
• 131  Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks’ gestation. Pediatrics113(6),e560–e563 (2004).
  MedlineGoogle Scholar
• 132  Bloom M, Roques-Gineste M, Fries F, Lelong-Tissier M. Pulmonary haemodynamics after surfactant replacement in severe neonatal respiratory distress syndrome. Arch. Dis. Child. Fetal Neonatal Ed.73(2),F95–F98 (1995).
  Medline CASGoogle Scholar
• 133  Cochrane CG, Revak SD, Merritt TA et al. The efficacy and safety of KL₄-surfactant in preterm infants with respiratory distress syndrome. Am. J. Respir. Crit. Care Med.153(1),404–410 (1996).
  Medline CASGoogle Scholar
• 134  Egberts J, Brand R, Walti H, Bevilacqua G, Bréart G, Gardini F. Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics100(1),e4–e4 (1997).
  Medline CASGoogle Scholar
• 135  Escobedo M, Gunkel J, Kennedy K et al. Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. J. Pediatr.144(6),804 (2004).
  MedlineGoogle Scholar
• 136  Femitha P, Joy R, Adhisivam B, Prasad K, Gane BD, Bhat V. Surfactant Replacement Therapy (SRT) in Respiratory distress syndrome (RDS). Curr. Pediatr. Res.16(2),134–136 (2012).
  Google Scholar
• 137  Horbar JD, Wright LL, Soll RF et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J. Pediatr.123(5),757–766 (1993).
  Medline CASGoogle Scholar
• 138  Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am. J. Perinatol.21(03),109–119 (2004).
  MedlineGoogle Scholar
• 139  Hudak ML, Farrell EE, Rosenberg AA et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J. Pediatr.128(3),396 (1996).
  Medline CASGoogle Scholar
• 140  Clark RH, Auten RL, Peabody J. A comparison of the outcomes of neonates treated with two different natural surfactants. J. Pediatr.139(6),828–831 (2001).
  Medline CASGoogle Scholar
• 141  Bloom BT, Clark RH. Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics116(2),392–399 (2005).
  MedlineGoogle Scholar
• 142  Ainsworth S, Beresford M, Milligan D et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks’ gestation: a randomised trial. Lancet355(9213),1387–1392 (2000).
  Medline CASGoogle Scholar
• 143  Sinha SK, Lacaze-Masmonteil T, Soler AVI et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics115(4),1030–1038 (2005).
  MedlineGoogle Scholar
• 144  Moya FR, Gadzinowski J, Bancalari E et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics115(4),1018–1029 (2005).
  MedlineGoogle Scholar
• 145  Ann Malloy C, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr.94(6),779–784 (2005).
  MedlineGoogle Scholar
• 146  Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics87(1),101–107 (1991).
  Medline CASGoogle Scholar
• 147  Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics92(1),135–139 (1993).
  Medline CASGoogle Scholar
• 148  Halliday HL, Speer CP, Robertson B. Treatment of severe meconium aspiration syndrome with porcine surfactant. Eur. J. Pediatr.155(12),1047–1051 (1996).
  Medline CASGoogle Scholar
• 149  Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics97(1),48–52 (1996).
  Medline CASGoogle Scholar
• 150  Mosca F, Colnaghi M, Castoldi F. Lung lavage with a saline volume similar to functional residual capacity followed by surfactant administration in newborns with severe meconium aspiration syndrome. Intensive Care Med.22(12),1412–1413 (1996).
  Medline CASGoogle Scholar
• 151  Lam BC, Yeung C. Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics103(5),1014–1018 (1999).
  Medline CASGoogle Scholar
• 152  Kaneko M, Watanabe J, Ueno E. Surfactant lavage and replacement in meconium aspiration syndrome with pulmonary hemorrhage. J. Perinatal Med.29(4),351–356 (2001).
  Medline CASGoogle Scholar
• 153  Schlössser RL, Veldman A, Fischer D, Allendorf A, von Loewenich V. Lavage with exogenous surfactant in neonatal meconium aspiration syndrome. Z. Geburtshilfe Neonatol.206(1),15–18 (2002 ).
  Medline CASGoogle Scholar
• 154  Wiswell TE, Knight GR, Finer NN et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics109(6),1081–1087 (2002).
  MedlineGoogle Scholar
• 155  Salvia-Roigés M, Carbonell-Estrany X, Figueras-Aloy J, Rodríguez-Miguélez J. Efficacy of three treatment schedules in severe meconium aspiration syndrome. Acta Paediatr.93(1),60–65 (2004).
  Medline CASGoogle Scholar
• 156  Szymankiewicz M, Gadzinowski J, Kowalska K. Pulmonary function after surfactant lung lavage followed by surfactant administration in infants with severe meconium aspiration syndrome. J. Matern. Fetal Med.16(2),125–130 (2004).
  CASGoogle Scholar
• 157  Lejeune T, Pfister RE. Surfactant lavage for extracorporeal membrane oxygenation-requiring meconium aspiration syndrome – a cheap alternative. Eur. J. Pediatr.164(5),331–333 (2005).
  Medline CASGoogle Scholar
• 158  Collaborative Study Group for Neonatal Respiratory Diseases Chinese. Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatr.94(7),896–902 (2005).
  MedlineGoogle Scholar
• 159  Dargaville PA, Mills JF, Headley BM et al. Therapeutic lung lavage in the piglet model of meconium aspiration syndrome. Am. J. Respir. Crit. Care Med.168(4),456–463 (2003).
  MedlineGoogle Scholar
• 160  Lo C-W, Jeng M-J, Chang F-Y et al. Therapeutic lung lavage with diluted surfactant in neonates with severe meconium aspiration syndrome. J. Chin. Med. Assoc.71(2),103–109 (2008).
  MedlineGoogle Scholar
• 161  Gadzinowski J, Kowalska K, Vidyasagar D. Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO. J. Perinatol.28,S56–S66 (2008).
  Medline CASGoogle Scholar
• 162  Bos A, Tibboel D, Hazebroek F, Molenaar J, Lachmann B, Gommers D. Surfactant replacement therapy in high-risk congenital diaphragmatic hernia. Lancet338(8777),1279 (1991).
  Medline CASGoogle Scholar
• 163  Lotze A, Knight GR, Anderson KD et al. Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J. Paediatr. Surg.29(3),407–412 (1994).
  Medline CASGoogle Scholar
• 164  Glick PL, Leach CL, Besner GE et al. Pathophysiology of congenital diaphragmatic hernia III: exogenous surfactant therapy for the high-risk neonate with CDH. J. Paediatr. Surg.27(7),866–869 (1992).
  Medline CASGoogle Scholar
• 165  Bae CW, Jang CK, Chung SJ et al. Exogenous pulmonary surfactant replacement therapy in a neonate with pulmonary hypoplasia accompaning congenital diaphragmatic hernia: a case report. J. Korean Med. Sci.11(3),265–270 (1996).
  Medline CASGoogle Scholar
• 166  Somaschini M, Locatelli G, Salvoni L, Bellan C, Colombo A. Impact of new treatments for respiratory failure on outcome of infants with congenital diaphragmatic hernia. Eur. J. Pediatr.158(10),780–784 (1999).
  Medline CASGoogle Scholar
• 167  Lally K, Lally P, Langham M et al. Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. J. Pediatr. Surg.39(6),829 (2004).
  MedlineGoogle Scholar
• 168  Van Meurs K. Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia? J. Pediatr.145(3),312–316 (2004).
  Medline CASGoogle Scholar
• 169  Van Houten J, Long W, Mullett M et al. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: an autopsy evaluation. J. Pediatr.120(2),S40–S44 (1992).
  Medline CASGoogle Scholar
• 170  Pandit PB, Dunn MS, Colucci EA. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics95(1),32–36 (1995).
  Medline CASGoogle Scholar
• 171  Pandit PB, O’brien K, Asztalos E, Colucci E, Dunn MS. Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant. Arch. Dis. Child. Fetal Neonatal Ed.81(1),F40–F44 (1999).
  Medline CASGoogle Scholar
• 172  Amizuka T, Shimizu H, Niida Y, Ogawa Y. Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. Eur. J. Pediatr.162(10),697–702 (2003).
  Medline CASGoogle Scholar
• 173  Walti H, Eacute, Paris-Llado J et al. Prophylactic administration of porcine-derived lung surfactant is a significant factor in reducing the odds for peri-intraventricular haemorrhage in premature infants. Neonatology81(3),182–187 (2002).
  CASGoogle Scholar
• 174  Willson DF, Thomas NJ, Markovitz BP et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury. JAMA293(4),470–476 (2005).
  Medline CASGoogle Scholar
• 175  Willson DF, Zaritsky A, Bauman LA et al. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit. Care Med.27(1),188–195 (1999).
  Medline CASGoogle Scholar
• 176  Willson DF, Jiao JH, Bauman LA et al. Calf’s lung surfactant extract in acute hypoxemic respiratory failure in children. Crit. Care Med.24(8),1316–1322 (1996).
  Medline CASGoogle Scholar
• 177  Pandit PB, Dunn MS, Kelly EN, Perlman M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics95(6),851–854 (1995).
  Medline CASGoogle Scholar
• 178  Yeh TF, Lin HC, Chang CH et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics121(5),e1310–e1318 (2008).
  MedlineGoogle Scholar
• 179  Laughon M, Bose C, Moya F et al. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics123(1),89–96 (2009).
  MedlineGoogle Scholar
• 180  Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol. Scand.42(7),805–810 (1998).
  Medline CASGoogle Scholar
• 181  Luchetti M, Ferrero F, Gallini C et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr. Crit. Care Med.3(3),261–268 (2002).
  MedlineGoogle Scholar
• 182  Herting E, Gefeller O, Land M, Van Sonderen L, Harms K, Robertson B. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics106(5),957–964 (2000).
  Medline CASGoogle Scholar
• 183  Harms K, Herting E. Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration61(6),348–352 (2009).
  Google Scholar
• 184  Fetter W, Baerts W, Bos A, Lingen RV. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr.84(1),14–16 (1995).
  Medline CASGoogle Scholar
• 185  Lotze A, Knight GR, Martin GR et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J. Pediatr.122(2),261–268 (1993).
  Medline CASGoogle Scholar
• 186  Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J. Pediatr.132(1),40–47 (1998).
  Medline CASGoogle Scholar
• 187  Ferrara TB, Hoekstra RE, Couser RJ et al. Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy. J. Pediatr.124(1),119–124 (1994).
  Medline CASGoogle Scholar
• 188  Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics92(2),191–196 (1993).
  Medline CASGoogle Scholar
• 189  Pelkonen AS, Hakulinen A, Turpeinen M, Hallman M. Effect of neonatal surfactant therapy on lung function at school age in children born very preterm. Pediatr. Pulmonol.25(3),182–190 (1998).
  Medline CASGoogle Scholar
• 190  Sleight E, Coombs R, Gibson A, Primhak R. Neonatal respiratory distress in near-term infants – consider surfactant protein B deficiency. Acta Paediatr.86(4),428–430 (1997).
  Medline CASGoogle Scholar